Probiotec Past Earnings Performance

Past criteria checks 2/6

Probiotec has been growing earnings at an average annual rate of 24.6%, while the Pharmaceuticals industry saw earnings growing at 47.3% annually. Revenues have been growing at an average rate of 24.6% per year. Probiotec's return on equity is 9.8%, and it has net margins of 3.9%.

Key information

24.6%

Earnings growth rate

19.5%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate24.6%
Return on equity9.8%
Net Margin3.9%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Probiotec (ASX:PBP) Is Increasing Its Dividend To A$0.03

Feb 26
Probiotec (ASX:PBP) Is Increasing Its Dividend To A$0.03

Probiotec (ASX:PBP) Has Affirmed Its Dividend Of AU$0.02

Feb 28
Probiotec (ASX:PBP) Has Affirmed Its Dividend Of AU$0.02

Revenue & Expenses Breakdown
Beta

How Probiotec makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:PBP Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232219470
30 Sep 2321810450
30 Jun 2321411440
31 Mar 2320913430
31 Dec 2220415410
30 Sep 2219314400
30 Jun 2218214380
31 Dec 211638340
30 Sep 211427310
30 Jun 211215280
31 Dec 201066240
30 Sep 201066220
30 Jun 201076210
31 Mar 20965190
31 Dec 19844180
30 Sep 19794170
30 Jun 19734170
31 Mar 19734180
31 Dec 18724190
30 Sep 18693190
30 Jun 18663190
31 Dec 17602180
30 Sep 17613180
30 Jun 17613180
31 Dec 16633190
30 Sep 16643200
30 Jun 16662200
31 Dec 15641220
30 Sep 15641220
30 Jun 15630230
31 Dec 1465-1240
30 Sep 14670240
30 Jun 14681250
31 Dec 13652250
30 Sep 13662260
30 Jun 13671270

Quality Earnings: PBP has high quality earnings.

Growing Profit Margin: PBP's current net profit margins (3.9%) are lower than last year (7.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PBP's earnings have grown significantly by 24.6% per year over the past 5 years.

Accelerating Growth: PBP's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PBP had negative earnings growth (-41%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16%).


Return on Equity

High ROE: PBP's Return on Equity (9.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.